Vanda Pharmaceuticals (VNDA) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
7 Jun, 2026Opening remarks and agenda
Meeting commenced at 9:15 A.M. with the CEO presiding and all directors introduced.
Virtual meeting rules and agenda were made available to participants.
Participation and discussion limited to official business and stockholders of record.
Board and executive committee updates
Three directors nominated to serve until the 2029 annual meeting: Richard W. Dugan, Charles C. Duncan, and Anne Sempowski Ward.
Shareholder proposals
No other nominations or proposals were received in accordance with company bylaws.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Vanda Pharmaceuticals
- Fanapt and NEREUS drove growth as BYSANTI approval and pipeline advances set stage for expansion.VNDA
Q2 2026 - Fanapt and milsaperidone drive growth, with up to six products targeted by 2026.VNDACantor Global Healthcare Conference 2025
- 2026 revenue guidance raised on new launches, with BYSANTI and NEREUS set to drive future growth.VNDAH.C. Wainwright 4th Annual BioConnect Investor Conference
- Strong product launches and pipeline progress position for substantial growth in 2026–2027.VNDACorporate presentation
- Revenue up 3% to $51.7M, Fanapt sales surged 26%, NEREUS launched, guidance raised.VNDAQ1 2026
- Proxy covers director elections, compensation, auditor ratification, and equity plan amendment.VNDAProxy filing
- Key votes include director elections, auditor ratification, and equity plan amendment.VNDAProxy filing
- BYSANTI and Nereus launches in 2026 drive growth amid expanding late-stage pipeline.VNDAThe Citizens Life Sciences Conference 2026
- Q1 2025 revenue up 5%, Fanapt surges, but net loss widens on R&D and licensing costs.VNDAQ1 2025